Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 SEK | +0.62% | 0.00% | +4.89% |
04-10 | Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 | CI |
02-22 | Newbury Pharmaceuticals Secures SEK9 Million Sales Order | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.89% | 7.41M | - | - | |
-12.59% | 8.23B | B | ||
+26.58% | 1.26B | - | ||
-13.82% | 339M | - | ||
+0.36% | 267M | - | ||
+8.33% | 220M | - | - | |
-45.37% | 82.2M | C | ||
-18.35% | 78.45M | - | - | |
+26.03% | 62.1M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- NEWBRY Stock
- Ratings Newbury Pharmaceuticals AB